A detailed history of High Point Advisor Group LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, High Point Advisor Group LLC holds 2,350 shares of NBIX stock, worth $294,948. This represents 0.02% of its overall portfolio holdings.

Number of Shares
2,350
Previous 1,925 22.08%
Holding current value
$294,948
Previous $265,000 1.89%
% of portfolio
0.02%
Previous 0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$114.58 - $153.15 $48,696 - $65,088
425 Added 22.08%
2,350 $270,000
Q2 2024

Aug 08, 2024

SELL
$130.86 - $143.19 $82,834 - $90,639
-633 Reduced 24.75%
1,925 $265,000
Q1 2024

May 14, 2024

BUY
$130.4 - $143.74 $6,259 - $6,899
48 Added 1.91%
2,558 $352,000
Q4 2023

Mar 26, 2024

BUY
$106.07 - $132.76 $35,215 - $44,076
332 Added 15.24%
2,510 $330,000
Q2 2022

Aug 15, 2022

BUY
$75.79 - $100.07 $165,070 - $217,952
2,178 New
2,178 $207,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track High Point Advisor Group LLC Portfolio

Follow High Point Advisor Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Point Advisor Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Point Advisor Group LLC with notifications on news.